Abstract
Although aromatase inhibitors are widely used as adjuvant endocrine treatment for hormone-sensitive early breast cancer, the optimal treatment strategy is controversial. Differences in trial design, endpoint definitions, and patient populations preclude straightforward trial comparisons. Standardized, consistent endpoint definitions, focused on efficacy outcomes (e.g., time to recurrence, time to distant recurrence), would allow for more meaningful comparisons. Disease-free survival and overall survival should be secondary endpoints, since they include deaths without recurrence, which can dilute and confuse efficacy evaluations. Distant metastasis is an excellent surrogate for breast cancer death and is available a few years earlier. These changes should lead to more rapid and reliable introduction of improved therapeutic strategies.
References
Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T SaphnerR Gray
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F BoccardoN Ragni
Jul 2, 2002·Lancet·M BaumUNKNOWN ATAC Trialists' Group
Mar 12, 2004·The New England Journal of Medicine·R Charles CoombesUNKNOWN Intergroup Exemestane Study
Nov 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric P WinerMark R Somerfield
Jan 11, 2005·Lancet·A HowellUNKNOWN ATAC Trialists' Group
Apr 13, 2005·Lancet·Jack Cuzick
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathleen I Pritchard
Aug 9, 2005·Lancet·Raimund JakeszUNKNOWN ABCSG and the GABG
Sep 8, 2005·Journal of the National Cancer Institute·Paul E GossJoseph L Pater
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettMichael Baum
Dec 31, 2005·The New England Journal of Medicine·UNKNOWN Breast International Group (BIG) 1-98 Collaborative GroupAron Goldhirsch
Jan 26, 2006·British Journal of Cancer·J CuzickA Howell
Jan 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan S CoatesAron Goldhirsch
Feb 20, 2007·Lancet·R C CoombesUNKNOWN Intergroup Exemestane Study
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clifford A HudisJo Anne Zujewski
Jun 15, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manfred KaufmannGunter von Minckwitz
Jun 29, 2007·Journal of the National Cancer Institute·Cornelis J A PuntJean-Yves Douillard
Aug 7, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN 10th St. Gallen conference
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe VialeAlan S Coates
Dec 18, 2007·The Lancet Oncology·Birgitte B RasmussenUNKNOWN BIG 1-98 Collaborative and International Breast Cancer Study Groups
Dec 18, 2007·The Lancet Oncology·John F ForbesMichael Baum
Jan 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettAman Buzdar
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P MamounasNorman Wolmark
Jul 1, 2008·Lancet·Jack Cuzick
Dec 30, 2008·Breast Cancer Research and Treatment·James MansellJulie C Doughty
Jun 19, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Aug 21, 2009·The New England Journal of Medicine·UNKNOWN BIG 1-98 Collaborative GroupAlan S Coates